Formulation and Drug Delivery

New Vaccine for HIV Using Lipid-Nanoparticle Technology

March 01, 2019

A project conducted by research institute CEA-Leti led to the development of a new HIV vaccine approach based on engineered lipid nanoparticles.

Valitacell, Solentim Collaborate to Accelerate Development of Breakthrough Medicines

February 22, 2019

Pharmaceutical Technology's In the Lab eNewsletter

Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.

FDA Reacts to Generic Drug Critics

February 22, 2019

In a statement, FDA Commissioner Scott Gottlieb laid out the case for the safety and effectiveness of generic drugs compared to brand drugs.

Mustang Bio, Nationwide Children’s Hospital Sign License Agreement for Oncolytic Virus Therapy

February 21, 2019

Mustang intends to combine an oncolytic virus with an interleukin-13 Rα2-(IL13Rα2)-specific chimeric antigen receptor to potentially enhance efficacy in treating glioblastoma multiforme.

Teva, Insilico Partner on Predictive Biomanufacturing Technology

February 21, 2019

Teva will apply Insilico’s technology for predictive biomanufacturing to create more efficient biomanufacturing processes.

Bharat Acquires GSK’s Chiron Behring Vaccines

February 21, 2019

India’s Bharat Biotech is set to acquire GlaxoSmithKline’s Chiron Behring Vaccines, a World Health Organization-prequalified global manufacturer of rabies vaccines.

FDA Encourages Development of Regenerative Medicines

February 20, 2019

The agency clarified the process for development programs for regenerative medicine therapies.

FDA Publishes Competitive Generic Therapy Guidance

February 15, 2019

The guidance explains the process of applying for competitive generic therapy designation.

Sanofi Gets FDA Approval for Nanobody-Based Therapeutic

February 15, 2019

The drug is approved in the United States specifically for treating acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder.

AbbVie, Teneobio Partner on Multiple Myeloma Treatment

February 15, 2019

The partners will collaborate on the development and commercialization of a B-cell maturation antigen-targeting immunotherapeutic for treating multiple myeloma.